https___magzentine.com_defence-minister-rajnath-singh-to-release-first-batch-of-drdo-anti-covid-drug-on-monday_.xml
https___tlnpost.com_2021_05_17_2968__1.xml
1.1 2.1 3.1 4.1 4.2 5.1 5.2 6.1 7.1 8.1 9.1 10.1 10.2 11.1 11.2 12.1 12.2 12.3 12.4 13.1 14.1 15.1 16.1 16.2 16.3 17.1 17.2 17.3 18.1
Defence Minister Rajnath Singh to release first batch of DRDO anti-Covid drug on Monday Defence Minister Rajnath Singh will release the first batch of DRDO-developed anti-Covid drug 2-DG on May 17. UPDATED: May 16, 2021 23:57 IST The first batch of the 2-deoxy-D-glucose (2-DG) drug developed by the Defence Research and Development Organisation (DRDO) for treatment of Covid-19 will be released by Defence Minister Rajnath Singh on Monday. He will be accompanied by Health Minister Harsh Vardhan. Hospitals will begin to receive supplies of the drug from Monday onwards. To start with, nearly 10,000 doses will be supplied to various hospitals in Delhi. The Drugs Controller General of India (DCGI) had on May 8 approved the drug for emergency use in moderate to severe cases of Covid-19. ALSO READ: Easy to produce, easier to consume: DRDO’s 2-DG drug for treatment of Covid patients | FAQs About 2-DG The anti-Covid therapeutic application of the drug 2-deoxy-D-glucose (2-DG) was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO in collaboration with Dr Reddy’s Laboratories (DRL), in Hyderabad. Clinical trial results show that the drug enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Covid patients treated with 2-DG showed a higher proportion of RT-PCR negative conversion. Patients treated with 2-DG also showed faster recovery from symptoms. A difference of 2.5 days was seen in the median time taken to achieve normalisation of specific vital signs parameters between those given the drug and those who were not. The drug comes in the form of powder in a sachet. It has to be dissolved in water and taken orally. The drug accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes it a unique drug. Clinical trials In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of the Centre for Cellular and Molecular Biology in Hyderabad and found that this molecule works effectively against the SARS-CoV-2 virus and inhibits viral growth. Based on these results, the DCGI’s Central Drugs Standard Control Organisation (CDSCO) permitted Phase-II clinical trials of 2-DG in Covid-19 patients in May 2020. In the Phase-II trials conducted till October last year, the drug was found to be safe for Covid-19 patients and led to significant improvement in their condition. Phase II-A was conducted in six hospitals and Phase II-B clinical trial was conducted at 11 hospitals across India. The Phase-II trial was conducted on a total of 110 patients. Based on successful results, DCGI further permitted the Phase-III clinical trials in November 2020. The Phase-III clinical trial was conducted on 220 patients between December 2020 and March 2021 at 27 Covid hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. Detailed data of the Phase-III clinical trial was presented to the DCGI. Source–https://www.indiatoday.in/india/story/rajnath-singh-release-first-batch-drdo-covid-drug-monday-1803273-2021-05-16
1.1 2.1 3.1 4.1
कोरोना भाइरसविरुद्ध भारतले बनाएको खाने औषधि सोमबार सार्वजनिक गरिएको छ।भारतको रक्षा अनुसन्धान तथा विकास संगठन डीआरडीओले विकास गरेको २–डीजी औषधि रक्षामन्त्री राजनाथ सिंह र स्वास्थ्यमन्त्री डा. हर्ष वर्द्धनले सार्वजनिक गरेको हिन्दुस्तान टाइम्सले जनाएको छ। हैदराबादस्थित डा. रेड्डिज प्रयोगशालामा यो औषधिको १० हजार डोज तयार भएको बताइएको छ।स्वास्थ्यमन्त्री हर्ष वर्द्धन भन्छन्,‘यस औषधिको सेवनले कोरोना संक्रमित चाँडै निको हुन्छन् र यसले अक्सिजनमा भर पर्नुपर्ने अवस्थालाई कम गर्छ।’२-डीजी पाउडरका रूपमा प्याकेटमा आउँछ, जसलाई पानीमा घोलेर पिउन सकिन्छ। ग्यास्ट्रिक र अपचको समस्यामा प्रयोग हुने औषधिजस्तै पानीमा घोलेर पिउने हो। यो औषधिले त्यस्ता संक्रमितलाई स्वस्थ हुन मद्दत पुर्याउँछ, जसलाई सास फेर्न समस्या हुन्छ। परीक्षणका क्रममा यो औषधिले अस्पतालमा भर्ना भएका बिरामीलाई सञ्चो पार्न सहयोग गर्नाका साथै अक्सिजनको आवश्यकता पनि घटाएको पाइयो। रक्षा मन्त्रालयले भनेको छ : जारी दोस्रो लहरको कोरोना महामारीका कारण ठूलो संख्यामा बिरामीलाई अक्सिजन दिनुपर्ने तथा अस्पताल भर्ना गर्नुपरेको छ। यस औषधिले अमूल्य जीवन बचाउने अपेक्षा गरिएको छ। साथै कोरोना संक्रमितलाई अस्पतालमा बस्नुपर्ने समय पनि घटाउनेछ।’ कोरोनासँग लडिरहेका बिरामीलाई यो औषधि निकै लाभकारी हुन्छ। यही मे १ देखि यो औषधिलाई मध्यम तथा गम्भीर लक्षणका कोरोना संक्रमितको उपचारमा सहायक विधिका रूपमा आपतकालीन प्रयोग गर्न डीसीजीआईले अनुमति दिइसकेको छ। २-डीजी औषधि भाइरसबाट संक्रमित कोषिकामा जम्मा हुन्छ र भाइरसको वृद्धि रोक्छ। औषधिको प्रभावबारे मन्त्रालयले भनेको छ : लक्षणयुक्त जुन जुन बिरामीमा यो औषधि प्रयोग गरिएको थियो, उपचार प्रक्रियाको मानक (एसओसी) भन्दाअघि नै उनीहरू ठीक भए। २-डीजी प्रयोग गरिएका धेरैजसो संक्रमितको पीसीआर परीक्षण गर्दा रिपोर्ट नेगेटिभ आए।’